Table 1.
The levels (ng/mg protein; mean±SD) of dopamine (DA), 3,4-dihydroxyphenyl-acetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in the prefrontal cortex (PFC) and striatum of the experimental groups. *indicates one measurement less due to method failure in some samples
| Brain | Analyte | Vehicle | LPS | Exendin4 | LPS + Exendin4 | Two-way ANOVA, |
| region | (n = 11) | (n = 7) | (n = 12) | (n = 11) | effect of Exendin-4 | |
| *(n = 10) | and LPS | |||||
| PFC | DA | 0.86±0.33 | 0.79±0.31 | 0.78±0.23 | 0.94±0.14 | unaltered |
| DOPAC | 0.17±0.14 | 0.17±0.07 | 0.13±0.07 | 0.21±0.05 | unaltered | |
| HVA | 0.21±0.29 | 0.33±0.16 | 0.18±0.25 | 0.37±0.21 | unaltered | |
| 5-HT | 6.88±1.00 | 7.19±1.63 | 7.48±1.66 | 7.32±1.19 | unaltered | |
| 5-HIAA | 6.70±0.82 | 6.88±1.38 | 6.11±1.57 | 7.03±2.43 | unaltered | |
| DOPAC/DA ratio | 0.19±0.10 | 0.23±0.10 | 0.16±0.05 | 0.22±0.05 | Significant increasing effect of LPS, p = 0.026 | |
| HVA/DA ratio | 0.22±0.31 | 0.39±0.22 | 0.18±0.25 | 0.39±0.21 | Significant increasing effect of LPS, p = 0.03 | |
| Striatum | DA | 154.02±22.32 | 160.12±20.24 | 164.28±33.40 | 184.22±28.17* | Trend towards increasing effect of Exendin-4, p = 0.059 |
| DOPAC | 14.50±2.84 | 16.32±2.28 | 15.09±3.38 | 16.21±1.99* | unaltered | |
| HVA | 10.89±1.85 | 12.42±2.56 | 11.06±2.83 | 14.04±3.66* | Significant increasing effect of LPS, p = 0.017 | |
| 5-HT | 7.95±1.23 | 7.10±1.35 | 6.77±1.53 | 7.00±3.30* | unaltered | |
| 5-HIAA | 13.35±1.27 | 14.20±3.89 | 11.64±2.80 | 14.69±5.52* | Significant increasing effect of LPS, p = 0.047 | |
| DOPAC/DA ratio | 0.095±0.02 | 0.1028±0.01 | 0.0923±0.01 | 0.0892±0.01* | Trend towards decreasing effect of Exendin-4, p = 0.1 | |
| HVA/DA ratio | 0.071±0.00 | 0.077±0.01 | 0.067±0.01 | 0.076*±0.01 | Significant increasing effect of LPS, p = 0.031 |